BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 32173363)

  • 1. A novel histone acetyltransferase inhibitor A485 improves sensitivity of non-small-cell lung carcinoma cells to TRAIL.
    Zhang B; Chen D; Liu B; Dekker FJ; Quax WJ
    Biochem Pharmacol; 2020 May; 175():113914. PubMed ID: 32173363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ABC294640, a sphingosine kinase 2 inhibitor, enhances the antitumor effects of TRAIL in non-small cell lung cancer.
    Yang J; Yang C; Zhang S; Mei Z; Shi M; Sun S; Shi L; Wang Z; Wang Y; Li Z; Xie C
    Cancer Biol Ther; 2015; 16(8):1194-204. PubMed ID: 26054751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
    Howe GA; Xiao B; Zhao H; Al-Zahrani KN; Hasim MS; Villeneuve J; Sekhon HS; Goss GD; Sabourin LA; Dimitroulakos J; Addison CL
    PLoS One; 2016; 11(3):e0150567. PubMed ID: 26962872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel histone deacetylase inhibitors derived from Magnolia officinalis significantly enhance TRAIL-induced apoptosis in non-small cell lung cancer.
    Liu Y; Tong Y; Yang X; Li F; Zheng L; Liu W; Wu J; Ou R; Zhang G; Hu M; Liu Z; Lu L
    Pharmacol Res; 2016 Sep; 111():113-125. PubMed ID: 27268146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Schedule-dependent cytotoxicity of sunitinib and TRAIL in human non-small cell lung cancer cells with or without EGFR and KRAS mutations.
    Bao YX; Zhao XD; Deng HB; Lu CL; Guo Y; Lu X; Deng LL
    Cell Oncol (Dordr); 2016 Aug; 39(4):343-52. PubMed ID: 27016208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TNF-related apoptosis-inducing ligand enhances vinorelbine-induced apoptosis and antitumor activity in a preclinical model of non-small cell lung cancer.
    Zhu K; Fang W; Chen Y; Lin S; Chen X
    Oncol Rep; 2014 Sep; 32(3):1234-42. PubMed ID: 25017445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
    Li F; Zhu T; Cao B; Wang J; Liang L
    Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone acetyltransferase inhibitor CPTH6 preferentially targets lung cancer stem-like cells.
    Di Martile M; Desideri M; De Luca T; Gabellini C; Buglioni S; Eramo A; Sette G; Milella M; Rotili D; Mai A; Carradori S; Secci D; De Maria R; Del Bufalo D; Trisciuoglio D
    Oncotarget; 2016 Mar; 7(10):11332-48. PubMed ID: 26870991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tanshinone IIA induces TRAIL sensitization of human lung cancer cells through selective ER stress induction.
    Kim EO; Kang SE; Im CR; Lee JH; Ahn KS; Yang WM; Um JY; Lee SG; Yun M
    Int J Oncol; 2016 May; 48(5):2205-12. PubMed ID: 26983803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The novel thymidylate synthase inhibitor trifluorothymidine (TFT) and TRAIL synergistically eradicate non-small cell lung cancer cells.
    Azijli K; van Roosmalen IA; Smit J; Pillai S; Fukushima M; de Jong S; Peters GJ; Bijnsdorp IV; Kruyt FA
    Cancer Chemother Pharmacol; 2014 Jun; 73(6):1273-83. PubMed ID: 24744163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Curcumin lowers erlotinib resistance in non-small cell lung carcinoma cells with mutated EGF receptor.
    Li S; Liu Z; Zhu F; Fan X; Wu X; Zhao H; Jiang L
    Oncol Res; 2013; 21(3):137-44. PubMed ID: 24512728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
    Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
    Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells.
    Kandasamy K; Srivastava RK
    Cancer Res; 2002 Sep; 62(17):4929-37. PubMed ID: 12208743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.
    Tong X; Tanino R; Sun R; Tsubata Y; Okimoto T; Takechi M; Isobe T
    Respir Res; 2019 Dec; 20(1):270. PubMed ID: 31791326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gambogenic acid inhibits fibroblast growth factor receptor signaling pathway in erlotinib-resistant non-small-cell lung cancer and suppresses patient-derived xenograft growth.
    Xu L; Meng X; Xu N; Fu W; Tan H; Zhang L; Zhou Q; Qian J; Tu S; Li X; Lao Y; Xu H
    Cell Death Dis; 2018 Feb; 9(3):262. PubMed ID: 29449529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinome profiling of non-canonical TRAIL signaling reveals RIP1-Src-STAT3-dependent invasion in resistant non-small cell lung cancer cells.
    Azijli K; Yuvaraj S; Peppelenbosch MP; Würdinger T; Dekker H; Joore J; van Dijk E; Quax WJ; Peters GJ; de Jong S; Kruyt FA
    J Cell Sci; 2012 Oct; 125(Pt 19):4651-61. PubMed ID: 22797920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of death receptor translocation into lipid rafts in acquired TRAIL-resistant NSCLC cells.
    Ouyang W; Yang C; Zhang S; Liu Y; Yang B; Zhang J; Zhou F; Zhou Y; Xie C
    Int J Oncol; 2013 Feb; 42(2):699-711. PubMed ID: 23258590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
    Dong S; Zhang XC; Cheng H; Zhu JQ; Chen ZH; Zhang YF; Xie Z; Wu YL
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):707-16. PubMed ID: 22941374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of the Apoptotic Resistance of Non-Small-Cell Lung Carcinoma towards TRAIL by Natural Product Toosendanin.
    Li X; You M; Liu YJ; Ma L; Jin PP; Zhou R; Zhang ZX; Hua B; Ji XJ; Cheng XY; Yin F; Chen Y; Yin W
    Sci Rep; 2017 Feb; 7():42748. PubMed ID: 28209994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Molecular Regulators of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)-Induced Apoptosis in NSCLC Cells.
    Ge Y; Yan D; Deng H; Chen W; An G
    Clin Lab; 2015; 61(12):1855-63. PubMed ID: 26882807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.